Skip to main content

Stevanato Group S.p.A. (STVN) Stock Analysis

HoldModerate Confidence

Healthcare · Medical Instruments & Supplies

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two... Read more

$14.18+52.6% upside
Score 5.6/10Target $21.64Reward/Risk 16.4:1

TrendMatrix rates Stevanato Group S.p.A. (STVN) as Hold with moderate confidence. The stock trades at $14.18 with +52.6% upside to the $21.64 price target. Overall score: 5.6/10 across 10 analysis dimensions. Reward/risk ratio: 16.4:1.

Passes 3/5 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.

Val7.4Qual4.5Grw6.8Mom1.9Sent6.7Ins5.0Peer3.6Tech6.2Risk7.15.6OVERALL

Investment Thesis

+ Sector modifier (): +1.2
+ Attractive valuation
+ Analyst upside: 53%
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5)
- Negative momentum
- Below 200-day MA

Fundamentals

P/E (TTM)24.7
P/E (Fwd)17.1
Mkt Cap$4.0B
EV/EBITDA15.4
Profit Mgn11.8%
ROE9.7%
Rev Growth4.8%
Beta0.57
Dividend0.42%
Analysts17
Frequently Asked Questions
Is STVN stock a buy right now?

TrendMatrix rates Stevanato Group S.p.A. (STVN) as Hold with moderate confidence. Score 5.6/10.

What is the STVN stock price target?

Take-profit target: $21.64 (+52.6% upside). Reward/risk ratio: 16.4:1. Stop-loss: $13.72.

What are the risks of investing in STVN?

V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Negative momentum; Below 200-day MA.

Is STVN overvalued or undervalued?

Stevanato Group S.p.A. trades at a P/E of 24.7 (forward 17.1). TrendMatrix value score: 7.4/10. Verdict: Hold.

What do analysts say about STVN?

17 analysts cover STVN with a consensus score of 4.2/5. Average price target: $25.

What does Stevanato Group S.p.A. do?Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide...

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Related stocks: RGEN (Repligen Corporation) · MMSI (Merit Medical Systems, Inc.) · SOLV (Solventum Corporation) · RMD (ResMed Inc.) · NVST (Envista Holdings Corporation)
30 OVERSOLD
<20d<50d<200dDEATH CROSSSupp $14.14Res $17.59

Price Targets

$14
$22
Upside+52.6%
Reward/Risk16.4:1

Position Sizing

ConvictionNONE
Suggested %0.5%
Max %1%
RegimeRISK_OFF

Risk Alerts

! MOMENTUM:1.9<5.0
! DEATH_CROSS:HARD_BLOCK
FALLING KNIFESuitability: Aggressive
Risk/Reward 10.5>=2.0
Insider activity: OK
No SEC red flags
Momentum 1.9<5.0
Death cross (50MA < 200MA)